Biogen: proposed transaction with Samsung Bioepis

(CercleFinance.com) - Biogen announces a proposed transaction with Samsung Bioepis, which would provide Biogen with exclusive marketing rights to two ophthalmology bio-similars relating to Lucentis and Eylea, in the US, Canada, Europe, Japan and Australia.


In addition, it would acquire exclusive marketing rights to its anti-TNF portfolio, including Benepali, Flixabi and Imraldi in China, as well as an option to extend the existing commercial agreement on this portfolio to Europe.

Biogen will make an initial payment of 100 million dollars to Samsung Bioepis, to which milestone payments of up to 210 million dollars could be added. It plans to record research and development expenses of around 65 million dollars.


Copyright (c) 2019 CercleFinance.com. All rights reserved.